Paternal Use of Metformin During the Sperm Development Period Preceding Conception and Risk for Major Congenital Malformations in Newborns.

ABSTRACT:

Background

Metformin is the most used oral antidiabetic medication. Despite its established safety profile, it has known antiandrogenic and epigenetic modifying effects. This raised concerns about possible adverse developmental effects caused by genomic alterations related to paternal use of metformin during the spermatogenesis period preceding conception.

Objective

To assess the potential adverse intergenerational effect of metformin by examining the association between paternal metformin use during spermatogenesis and major congenital malformations (MCMs) in newborns.

Design

Nationally representative cohort study.

Setting

A large Israeli health fund.

Participants

383 851 live births linked to fathers and mothers that occurred in 1999 to 2020.

Measur

SUBMITTER: Rotem RS 

PROVIDER: S-EPMC12538655 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature